BIN2 inhibition suppress ovarian cancer progression meanwhile protect ovarian function through downregulating HDAC1 and RPS6 phosphorylation respectively

Clin Transl Med. 2024 Oct;14(10):e70051. doi: 10.1002/ctm2.70051.

Cong-Rong Li^{1

2

3

4}, Shi-Ya Xie^{1

2

3

4}, Shu-Ping Zhang^{1

2

3

4}, Yan-Jie Yang^{1

2

3

4}, Li-Li Yang⁵, Ying Cao⁵, Li-Li Wang², Feng-Yu Zhu², Ruo-Lei Wang², Zhi-Xia Yang¹, Chen-Chen Cui⁶, Yan-Ru Li⁶, Jia-Ning Xu⁶, Feng Yue⁶, Pei-Zhe Tian⁶, Qian Wang⁶, Hong-Jie Yao⁷, Yi-Chun Guan⁸, Shao-Di Zhang⁶, Xiao-Yan Ying⁵, Dong Zhang^{1

2

3

4}, Cui-Lian Zhang⁶

¹ Department of Gynaecology and Obstetrics, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
² State Key Lab of Reproductive Medicine and Offspring Health, Nanjing Medical University, Nanjing, Jiangsu, China.
³ NHC Key Laboratory of Study on Abnormal Gametes and Reproductive Tract, Anhui Medical University, Hefei, Anhui, China.
⁴ Key Laboratory of Population Health Across Life Cycle (Anhui Medical University), Ministry of Education of the People's Republic of China, Hefei, Anhui, China.
⁵ Department of Gynaecology and Obstetrics, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
⁶ Reproductive Medical Center, Henan Provincial People's Hospital & People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.
⁷ Guangzhou National Laboratory, University of Chinese Academy of Sciences, Guangzhou, Guangdong, China.
⁸ Center for Reproductive Medicine, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

No abstract available

Publication types